Trump: Agent Of Chaos (a.k.a. “The Kraken”)

December 28, 2017

Most people don’t understand Trump’s domestic and international intentions, believing that he and his team are “ruining everything” because they’re “hopelessly incompetent”, though the fact of the mat…

Beijing Complicates Washington’s Afghan Strategy

December 28, 2017

Opinion

After a meeting in Beijing on Tuesday of the China-Afghanistan-Pakistan Dialogue, a newly created trilateral format, Chinese Foreign Minister Wang Yi made a major announcement that Beijing and Islamab…

Is the Buildup to World War I Being Repeated for WWIII?

December 28, 2017

Opinion

The great scholar of Turkish history, Taner Akçam, has described today’s geopolitics — the alliances and hostilities toward possibly another World War — as being not ideologically based like WW II, bu…

The Quad: US Searches Edge of Asia for Allies to Contain Beijing

December 28, 2017

Opinion

There has been a recent buzz promoted around the so-called Quadrilateral Security Dialogue (Quad) – a coalition of sorts counting the United States, India, Australia, and Japan as members. Promoted by…

Was Yemen the Most Important Story of 2017 and Why Was it Under-Reported?

December 28, 2017

Opinion

2017 was a year which was dominated by the new US President Donald Trump, a General Election in the UK and the ongoing Brexit negotiations, terror attacks in Britain, and the crisis in North Korea. Bu…

Did the FBI Conspire to Stop Trump?

December 28, 2017

Opinion

The original question the FBI investigation of the Trump campaign was to answer was a simple one: Did he do it? Did Trump, or officials with his knowledge, collude with Vladimir Putin's Russia to hack…

US Prepares for Forcible Entry Operations in Remote Theaters of War

December 28, 2017

Opinion

One area where America has a significant advantage over any putative adversary is in logistics. No other nation can challenge the US ability to conduct overseas operations, deploy and sustain joint fo…

Price Gouging? Cancer Drug Price Spikes From $50 to $768 Per Pill After Change of Owner

December 28, 2017

Opinion

A long-standing medication for cancer has become almost unaffordable for most of patients, as its price has skyrocketed 1,500 percent over four years. The company behind the drug is under fire. The re…